In a statement here, Mr Ritha Chandrachud, Vice president (India Sales) of Dr Reddy's Laboratories, which is bringing the findings of the study to India in association with ACC, said, the study, being heralded as one of the most important cardiovascular studies in nearly a decade, would help doctors to understand how people with the highest risk of cardiovascular diseases can be protected from heart attacks and strokes.
The study had proved that 'Telmisartan' was as protective as the current gold standard, Ramipril, in reducing the risk of cardiovascular death, myocardial infarction, stroke, and hospitalisation for congestive heart failure in a broad cross-section of high-risk cardiovascular patients and was better tolerated.
Mr Chandrachud said, ''We are very eagerly awaiting the results of this study and are proud to take this initiative to get ONTARGET(R) to India. We are very sure that this trial will be of immense use to doctors in treating hypertensive patients.'' The goal of ONTARGET(R) was to fully understand the potential of ARBs so that physicians could offer an effective and tolerable treatment regimen to the broadest range of patients, he added.